Kiniksa Pharmaceuticals International (KNSA) Price to Book (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Price to Book for 9 consecutive years, with 15.25 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book rose 84.17% year-over-year to 15.25; the trailing twelve-month figure through Jun 2026 stood at 15.25 (up 84.17% YoY), and the FY2025 full-year result was 11.11, up 69.45% from the prior year.
• Price to Book climbed to 15.25 in Q2 2026 per KNSA's latest filing, from 12.21 in the prior quarter.
• Across five years, Price to Book topped out at 15.25 in Q2 2026 and bottomed at 3.85 in Q1 2023.
• Historically, Price to Book has averaged 7.75 across 5 years, with a median of 6.82 in 2024.
• The sharpest annual moves came in 2023 and 2026: Price to Book sank 53.47% in 2023, then surged 84.17% in 2026.
• Over 5 years, Price to Book stood at 5.27 in 2022, then rose by 6.93% to 5.64 in 2023, then advanced by 16.25% to 6.55 in 2024, then surged by 69.45% to 11.11 in 2025, then surged by 37.31% to 15.25 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 15.25, 12.21, and 11.11 for Q2 2026, Q1 2026, and Q4 2025 respectively.